6MW3511

6MW3511 is a **bifunctional recombinant fusion protein drug** developed as an investigational therapy for advanced solid tumors. It is designed to block **PD-L1 (programmed death-ligand 1)** and **TGF-β2 (transforming growth factor beta 2)** mediated immune checkpoint pathways. Specifically, it consists of humanized anti-PD-L1 nanobodies linked to TGF-β receptor II mutants, an arrangement that enables dual blockade of PD-1/PD-L1 and TGF-β/TGF-βR signals. This dual inhibition mechanism aims to overcome immunosuppression in the tumor microenvironment—enhancing anti-tumor immune responses and improving tumor penetration. Preclinical studies have shown promising efficacy and tolerability in animal models. The drug is being developed as an intravenous injection for treatment of advanced malignant solid neoplasms, including multiple selected tumor types[1][3][5].

Brand names

6MW3511

Other names

6MW3511